Piribedil dihydrochloride, D2/D3 dopamine receptor agonist (ab146432)

Overview

  • Product name

    Piribedil dihydrochloride, D2/D3 dopamine receptor agonist
  • Description

    D2/D3 dopamine receptor agonist. D3 selectivity demonstrated in vitro.
  • Biological description

    D2/D3 dopamine receptor agonist. D3 selectivity demonstrated in vitro. Improves attentional dysfunction in combination with L-DOPA.
  • Purity

    > 99%
  • CAS Number

    1451048-94-4
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine dihydrochloride
  • Molecular weight

    371.27
  • Molecular formula

    C16H18N4O2.2HCl
  • Storage instructions

    Store at Room Temperature. The product can be stored for up to 12 months.
  • Solubility overview

    Soluble in water to 25 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    Cl.Cl.c1cc(cc2OCOc12)CN3CCN(CC3)c4ncccn4
  • Source

    Synthetic

References

This product has been referenced in:

  • Turle-Lorenzo N  et al. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. J Pharmacol Exp Ther 319:914-23 (2006). Read more (PubMed: 16920993) »
  • Cagnotto A  et al. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur J Pharmacol 313:63-7 (1996). Read more (PubMed: 8905329) »
  • Smith LA  et al. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol 29:112-25 (0). Read more (PubMed: 16772809) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab146432.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up